Vermillion (VRML) +14.4% premarket after announcing "positive" top-line results from its OVA1...

|By:, SA News Editor

Vermillion (VRML) +14.4% premarket after announcing "positive" top-line results from its OVA1 ovarian cancer diagnostic from a clinical study. VRML says OVA1 represents "a new class of software-based diagnostics"; it is the first protein-based, in vitro diagnostic multivariate index assay cleared by the FDA.